New results published at major dementia conference further validate company’s ICA platform’s capabilities and suitability for early disease detection VANCOUVER,…
Read More
We investigated the link between participant’s performance in ICA test and their cortical volume and thickness; we were further interested…
Electroencephalography (EEG) has been commonly used to measure brain alterations in the early stage of Alzheimer’s disease. However the reported…
The Integrated Cognitive Assessment (ICA) test is based on humans’ strong reaction to animal stimuli, and the ability of a…
VANCOUVER, May 26, 2020 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN; FWB: 1UB; OTCQB: CGNSF) today announced the…
Background: Cognitive impairment is common in patients with multiple sclerosis (MS). Accurate and repeatable measures of cognition have the potential…
VANCOUVER, April 1, 2020 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN; FWB: 1UB; OTCQB: CGNSF) is continuing to…
VANCOUVER, Feb. 18, 2020 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN; FWB: 1UB; OTCQB: CGNSF) has today reported…
VANCOUVER, Jan. 21, 2020 /CNW/ – Cognetivity Neurosciences Ltd. (the “Company” or “Cognetivity”) (CSE: CGN; FWB: 1UB; OTCQB: CGNSF) today announced that…
Cognetivity Neurosciences announces regulatory approval of first CE-marked medical device Vancouver, British Columbia, January 7, 2020 – Cognetivity Neurosciences…
